Bernhard-Nocht-Institut Fuer Tropenmedizin
- Address
- Bernhard-Nocht-Straße 74, St. Pauli, 20359 Hamburg, Germany
Virus Diseases
At the Bernhard-Nocht-Institut Fuer Tropenmedizin in Hamburg, clinical research is focused on virus diseases, with studies centered on major infectious threats such as ebola virus infection, cytomegalovirus infection, chronic hepatitis B, and SARS-CoV-2. The trials are designed to evaluate vaccine protection, immune response, and overall safety in healthy volunteers and at-risk groups.
- Research on ebolavirus vaccine strategies to understand how long protection lasts and whether booster vaccination strengthens immunity.
- Studies of CMV vaccine candidates aimed at preventing primary infection and assessing safety and tolerability.
- Trials in hepatitis B exploring therapeutic vaccination approaches to improve immune control of chronic infection.
This work highlights the site’s role in advancing infectious disease prevention and vaccine research, with a strong emphasis on improving immune protection against serious viral illnesses.
Vaccine Development and Immunology
The clinical trial program also reflects a broader focus on vaccine development and immunology, including studies that test new vaccine concepts for COVID-19, ebola, CMV, and hepatitis B. The main purpose is to determine whether these candidates are safe, trigger a strong immune response, and may offer better protection than existing approaches.
- Evaluation of a COVID-19 vaccine booster to see how well it enhances immune responses in healthy adults.
- Assessment of therapeutic hepatitis B vaccination for its ability to support immune control of chronic infection.
- Immunogenicity studies of ebolavirus vaccination to support prevention in people with potential occupational exposure.
These studies show a clear emphasis on translating laboratory expertise into practical clinical trials that can improve prevention and treatment options for viral diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Bernhard-Nocht-Institut Fuer Tropenmedizin
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril® in Adults | Sanofi Pasteur | Phase II | Not Recruiting | Oct 2021 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 1 | Unknown | 2022-02-03 | 2022-02-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.